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Purpose: Vision loss is one of the most common complications of aging, even in individuals with no diagnosed ocular
disease. Increasing age induces structural alterations and functional impairments in retinal neurons and microvasculature
linked to the activation of proinflammatory signaling pathways. Commonalities between the effects of aging and those
observed with diabetes, including visual impairment, vascular dysfunction, and increased inflammatory response, have
led to the hypothesis that diabetes-associated pathologies reflect an “advanced aging” phenotype. The goal of this study
was to investigate the effects of aging on retinal mRNA expression of neurovascular and inflammatory transcripts
previously demonstrated to be regulated with diabetes.
Methods: The relative expression of 36 genes of interest previously identified as consistently regulated with diabetes was
assessed in retinas of Young (3 month), Adult (12 month), and Aged (26 month) Fischer 344 x Brown Norway (F1) hybrid
rats using quantitative PCR. Serum samples obtained at sacrifice were assayed to determine serum glucose levels.
Results: Eleven inflammation- and microvascular-related genes previously demonstrated to be upregulated in young
diabetic rats (complement component 1 s subcomponent [C1s], chitinase 3-like 1 [Chi3L1], endothelin 2 [Edn2], guanylate
nucleotide binding protein 2 [Gbp2], glial fibrillary acidic protein [Gfap], intracellular adhesion molecule 1 [Icam1], janus
kinase 3 [Jak3], lipopolysaccharide-induced TNF factor [Litaf], complement 1-inhibitor [Serping1], signal transducer and
activator of transcription 3 [Stat3], tumor necrosis factor receptor subfamily member 12a [Tnfrsf12a]) demonstrated
progressively increasing retinal expression in aged normoglycemic rats. Additionally, two neuronal function–related genes
(glutamate receptor ionotropic NMDA 2A [Grin2a] and polycomb group ring finger 1 [Pcgf1]) and one inflammation-
related gene (pigment epithelium-derived growth factor [Pedf]) displayed patterns of expression dissimilar to that
previously demonstrated with diabetes.
Conclusions: The commonalities in retinal age-related and diabetes-induced molecular alterations provide support for
the hypothesis that diabetes and aging engage some common para-inflammatory processes. However, these results also
demonstrate  that  while  the  retinal  genomic  response  to  diabetes  and  aging  share  commonalities,  they  are  not
superimposable phenotypes. The observed changes in retinal gene expression provide further evidence of retinal alterations
in neurovascular and inflammatory processes across the adult rat lifespan; this is indicative of para-inflammation that may
contribute to the functional impairments that occur with advanced age. The data also suggest the potential for an additive
effect of aging and diabetes in the development of diabetic complications.
Even in the absence of ocular disease, deteriorating visual
function is one of the most common complications of aging
[1,2].  Numerous  aspects  of  vision,  ranging  from  general
acuity to night vision, decline with advancing age, suggesting
broad  retinal  dysfunction  [3,4].  For  example,  contrast
sensitivity (spatial resolution) decreases at around 50 years of
age in humans, and deficits of temporal processing (motion
sensitivity)  are  evident  by  60  years  [5].  This  effect  is
exacerbated by low-light (scotopic) conditions [6] and likely
reflects  retinal  dysfunction  rather  than  decreased  retinal
illuminance, since age-related decreases in pupil diameter
actually  appear  to  improve  contrast  sensitivity  [7].  Rod-
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mediated scotopic vision is impaired sooner and to a greater
extent  than  photopic  vision,  and  recovery  latency  after
photobleaching  is  significantly  increased  with  aging  [8].
Importantly,  these  visual  deficits  occur  even  in  subjects
without age-related pathology (e.g., maculopathy, glaucoma)
and  with  good  acuity,  and  worsen  progressively  with
increasing age [4,6-8]. Neurophysiological mechanisms for
age-related  vision  impairment  are  reflected  by  altered
electrophysiological  responses  of  photoreceptors,  bipolar
cells, and ganglion cells in the peripheral retina and fovea.
These cells, which mediate signal detection, integration, and
output,  exhibit  increased  response  latency,  decreased
potential  amplitude,  and  slowed  temporal  adaptation  [2,
9-13],  suggesting  decreased  sensitivity  and  signal
transduction with aging in the neural retina.
The retinal microvasculature also undergoes age-related
changes,  including  altered  ocular  blood  flow  and  loss  of
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1261barrier  integrity  [14].  In  clinically  healthy  adults  with  no
potentially confounding cardiovascular symptoms, regulative
retinal arterial constriction decreases drastically with aging,
and  may  reflect  the  functional  outcome  of  dysregulated
cellular and biochemical barrier composition [15]. Retinal
pigment  epithelium  (RPE)  cells  play  integral  roles  in
neuroretinal  adhesion  and  metabolic  support,  as  well  as
photoreceptor outer segment phagocytosis. As such, they are
susceptible to the accumulation of photoreactive molecules,
oxidized pigments, and toxic drusen deposits, and subsequent
inflammatory  response  [16-19].  Indeed,  age-related
impairment of the blood-retina barrier has been described in
aged  rats,  which  exhibit  significantly  increased  vascular
permeability, decreased tight junction protein expression, and
activation of major histocompatibility complex (MHC) class
II–positive  and  phagocytic  microglia  compared  to  their
younger adult counterparts [20]. The relationship between
impaired retinovascular integrity and retinal inflammation is
further  demonstrated  by  oxidation/inflammation-induced
RPE lesions and drusen deposition in a mouse model of age-
related retinal degeneration [21]. Age-related retinal vascular
lesions,  specifically  in  the  form  of  acellular  capillaries,
pericyte  loss,  and  terminal  deoxynucleotidyl  transferase
dUTP  nick  end  labeling  (TUNEL)-positive  apoptotic
endothelial cells, are highly similar to diabetes-related retinal
pathology in the rat, and appear to develop at an accelerated
rate with diabetes compared to normal aging [22]. Recent
findings  from  Swaroop  and  colleagues  integrate  these
processes  in  a  cell-specific  analysis  examining  the  rod
photoreceptor  transcriptome  with  aging  [23].  Altered
oxidative  phosphorylation,  barrier  integrity,  and
inflammatory homeostasis were observed in aged (12 month)
mice.
The  similarities  between  these  complications  and
common  effects  of  aging,  particularly  with  regard  to
functional deficits of the central nervous system (CNS), have
led  to  the  hypothesis  that  diabetes  contributes  to  the
development  of  an  “advanced  aging”  phenotype  [24-27].
Diabetes mellitus is a metabolic disorder characterized by loss
of insulin production or efficacy and glycemic dysregulation.
There are currently more than 20 million people in the United
States, nearly 8% of the population, living with diabetes and
susceptible to its associated complications. Type 1 (insulin-
dependent)  diabetes,  induced  by  peripubertal  autoimmune
destruction of insulin-producing pancreatic β-cells, comprises
approximately 10% of diabetes cases worldwide [28], with the
rest attributed to Type 2 (non-insulin-dependent) diabetes.
Although the etiologies of Type 1 and Type 2 diabetes differ,
the pathophysiology of these diseases is quite comparable,
leading over time to complications that include nephropathy,
peripheral  neuropathy,  cognitive  decline,  and  retinopathy
[28-33]. Although commonalities between aging and diabetes
have been investigated in the cortex and hippocampus, few
reports have focused on the retina, which is highly susceptible
to homeostatic dysregulation.
Type  1  diabetes  leads  to  some  degree  of  diabetic
retinopathy (DR) in approximately 95% of patients within 20
years of diagnosis, and although increasing awareness and
improved  glycemic  control  are  decreasing  the  projected
prevalence and severity of DR, it remains a leading cause of
new  cases  of  adult  blindness  worldwide  [28,34,35].
Symptoms of DR include early neuronal dysfunction followed
by  neuronal  apoptosis,  vascular  permeability,  and
upregulation  of  inflammatory  signaling  molecules.  Visual
impairment is associated with both manifest and subclinical
DR, and includes deficits of hue discrimination and contrast
sensitivity, delayed dark adaptation, abnormal visual fields,
and  decreased  overall  visual  acuity  [36-40].  Spatial
resolution,  or  contrast  sensitivity,  is  one  of  the  most
commonly studied aspects of vision consistently altered by
diabetes.  Early  research  in  the  field  of  retinopathy  has
demonstrated a generalized loss of central vision and hue
discrimination, as well as significant decreases in both static
and  dynamic  spatial  resolution  [41,42].  Many  of  these
symptoms are common in aging individuals without diabetes
or with other ocular conditions such as age-related macular
degeneration  or  glaucoma,  suggesting  a  progressive  age-
related visual impairment similar to that which occurs with
DR.  These  similarities  extend  from  the  functional  to  the
cellular  level,  as  alterations  in  ocular  blood  flow,  RPE
integrity, microvasculature, Bruch’s membrane morphology,
and electrophysiological correlates of neuronal function have
all been reported with both DR and advanced aging.
Research using rat models of diabetes have contributed
to  the  concept  of  DR  as  a  progressive  neurovascular
complication  that  includes  vascular,  inflammatory,  and
neuronal  components  [43-47].  We  have  extensively
characterized retinal transcriptomic and proteomic changes
with  diabetes  [45,46,48,49],  and  observed  induction  of
proinflammatory processes similar to those proposed with
aging [50]. These findings support the hypothesis that DR
represents an “advanced aging” phenotype; however, direct
comparisons of the retinal molecular phenotypes with DR and
aging are limited. To test the hypothesis that DR represents
an  advanced  aging  molecular  phenotype,  we  assessed  the
retinal expression of several diabetes-responsive genes across
the lifespan in a commonly employed rat model of aging, at
young-adulthood  (3  months),  adulthood  (12  months),  and
advanced age (26 months). We report both similarities and
differences between young-adult diabetic and aged rat retinal
gene expression patterns of the inflammatory, vascular, and
neuronal processes. This analysis provides novel insight into
the molecular changes that occur in the retina with increasing
age,  and  demonstrates  that  advanced  age  and  DR  have
common para-inflammatory processes.
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Animals: Pathogen-free Fischer 344 x Brown Norway (F1)
hybrid male rats, aged 3 months (Young-Adult), 12 months
(Adult), and 26 months (Aged; n=5 per group) were obtained
from  the  National  Institute  on  Aging  colony  at  Harlan
Industries (Indianapolis, IN), as described previously [51]. All
animals  were  singly  housed  in  laminar  flow  cages
(Polysulfone) in the Oklahoma University Health Sciences
Center (OUHSC) Barrier Facility with free access to food and
water (Purina Mills, Richmond, IN). The animal rooms were
maintained  on  a  12h:12h  light-dark  cycle  at  constant
temperature and humidity. The OUHSC animal facilities are
fully  accredited  by  the  Association  for  Assessment  and
Accreditation  of  Laboratory  Animal  Care.  All  animal
procedures were approved by the Institutional Animal Care
and Use Committee in accordance with the Public Health
Service  Policy  on  Humane  Care  and  Use  of  Laboratory
Animals and the National Research Council’s Guide for the
Care and Use of Laboratory Animals. Animals were sacrificed
by decapitation without anesthesia and the retinas rapidly
dissected, snap frozen in liquid nitrogen, and stored at −80 °C.
Trunk blood was also collected at the time of sacrifice. At
sacrifice, gross necropsy was performed and no visible tumors
were evident in any of the animals. Visual inspection of the
eye did not reveal cataracts in any of the animals.
Serum glucose quantitation: Trunk blood was collected into
15 ml conical tubes (VWR, West Chester, PA) and separated
by centrifugation at 2,500 rpm for 20 min at 4 °C. Following
serum isolation (upper phase), samples were stored at −80 °C
until  analysis.  Serum  samples  were  analyzed  for  glucose
levels  by  colorimetric  assay  (Glucose  Assay  Kit;  Abcam,
Cambridge, MA). Each sample was analyzed in technical
triplicates with a standard curve ranging from 0 to 20 nmol/
μl  using  a  SpectraMax  M2  microplate  reader  (Molecular
Devices, Sunnyvale, CA) at 570 nm absorbance.
RNA isolation and quantitation: Total RNA was isolated from
snap-frozen retinas using standard extraction, precipitation,
and purification methods, as previously described [45-48].
Briefly, retinas were homogenized in ice-cold Tri-Reagent
(Sigma-Aldrich, St. Louis, MO) using an automated Retsch
TABLE 1. GENE NAMES, ID NUMBERS, AND QPCR EXPRESSION ASSAYS.
Gene symbol GeneID number Gene name Gene expression assay
catalog #
Bbs2 113948 Bardet - Biedl syndrome 2 Rn00586096_m1
Birc4 63879 X-linked inhibitor of apoptosis Rn00573706_m1
C1S 192262 Complement component 1, s subcomponent Rn00594278_m1
Carhsp1 260416 Calcium regulated heat stable protein 1 Rn00596083_m1
Ccr5 117029 Chemokine, CC Motif, Receptor 5 Rn00588629_m1
Chi3L1 89824 Chitinase 3-like 1 Rn01490608_m1
Dcamkl1 83825 Doublecortin-like kinase 1 Rn00584294_m1
Edn2 24324 Endothelin 2 Rn00561135_m1
Ednrb 50672 Endothelin receptor B Rn00569139_m1
Elovl1 679532 Elongation of very long chain fatty acids Rn01403757_m1
Eno2 24334 Enolase 2 Rn00595017_m1
Gat3 79213 GABA transporter 3 Rn00577664_m1
Gbp2 171164 Guanylate nucleotide binding protein 2 Rn00592467_m1
Gfap 24387 Glial fibrillary acidic protein Rn00566603_m1
Grin2a 24409 Glutamate receptor, ionotropic, NMDA 2A Rn00561341_m1
Hspb1 24471 Heat shock 27 kDa protein 1 Rn00583001_g1
Icam1 25464 Intracellular adhesion molecule 1 Rn00564227_m1
Igf2 24483 Insulin - like growth factor 2 Rn00580426_m1
Jak3 25326 Janus Kinase 3 Rn00563431_m1
Kcne2 171138 Isk-related voltage-gated K+ channel 2 Rn02094913_s1
Lama5 140433 Laminin, alpha 5 Rn01415966_g1
Lgals3 83781 Lectin, galactoside-binding, soluble, 3 Rn00582910_m1
Lgals3bp 245955 Lectin, galactoside-binding, soluble, 3, binding protein Rn00478303_m1
Litaf 65161 Lipopolysaccharide-induced TNF factor Rn01424675_m1
Mccc1 294972 Methylcrotonoyl-CoA carboxylase 1 Rn01462252_m1
Nefh 24587 Neurofilament, heavy polypeptide Rn00709325_m1
Nppa 24602 Natriuretic peptide precursor A Rn00561661_m1
Nr3c1 24413 Nuclear receptor subfamily 3, group C, member 1 Rn01405584_m1
Pcgf 312480 Polycomb group ring finger 1 Rn01425394_g1
Pedf 287526 Pigment epithelium-derived growth factor Rn00709999_m1
Serping1 295703 Complement 1 - inhibitor Rn01485600_m1
Stat1 25124 Signal transducer and activator of transcription 1 Rn00583505_m1
Stat3 25125 Signal transducer and activator of transcription 3 Rn00562562_m1
Timp1 116510 Tissue inhibitor of metalloproteinase 1 Rn00587558_m1
Tnfrsf12 302965 Tumor necrosis factor receptor subfamily, member 12a Rn00710373_m1
Vegfa 83785 Vascular endothelial growth factor A Rn00582935_m1
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and stainless steel beads at 15 Hz for 1 min. 1-bromo-3-
chloropropane  (BCP;  Molecular  Research  Center,  Inc.,
Cincinnati,  OH)  was  added  in  1/10th  volume  to  separate
phases.  Isopropanol  was  then  added  at  1/10th  volume  to
precipitate RNA from the aqueous phase. Precipitated RNA
was purified using Qiagen RNeasy spin columns (Qiagen,
Inc., Valencia, CA) and subsequently resuspended in RNase-
free water. Quality and quantity were evaluated using the
RNA  6000  Nano  LabChip  with  an  Agilent  2100  Expert
Bioanalyzer (Agilent, Palo Alto, CA) and NanoDrop ND100
(Nanodrop, Wilmington, DE), respectively. RNA quality, as
measured  by  a  Bioanalyzer,  was  determined  using  RNA
integrity numbers, which are a measure of RNA degradation
ranging from 10 (intact) to 2 (degraded). RNA purity and
concentration,  as  measured  by  a  NanoDrop
spectrophotometer, was determined by absorbance at 260 and
280 nm.
Quantitative  reverse  transcription  PCR:  Following  RNA
isolation and quality control, cDNA was synthesized using the
ABI  High  Capacity  cDNA  Reverse  Transcription  Kit
(Applied  Biosystems  Inc.,  Foster  City,  CA)  according  to
standard protocols [46,49]. Briefly, 2× reverse transcription
(RT) master mix was prepared by mixing 2 μl 10× RT Buffer,
0.8 μl 25× 100 mM deoxynucleotide triphosphates (dNTPs),
2  μl  10×  random  primers,  1  μl  MultiScribe  Reverse
Transcriptase, 1 μl RNase Inhibitor, and 3.2 μl nuclease-free
water per reaction (total of 15 reactions) for a total of 10 μl
master mix per reaction. Total RNA (1 μg/10 ul) was pipetted
into each well followed by 10 μl of the prepared 2× master
mix. Reverse transcription was performed using a GeneAmp
PCR  System  9700  (Applied  Biosystems  Inc.)  with  the
following settings: Step 1) 25 °C – 10 min; 2) 37 °C – 2 h; 3)
85 °C – 5 s; 4) hold at 4 °C.
Quantitative  PCR  analysis  was  performed  using  a
7900HT Sequence Detection System (Applied Biosystems
Inc.), 384-well optical plates, and Assay-On-Demand gene
expression assays containing the gene-specific primers and
probes listed in Table 1 (Applied Biosystems Inc.) [46,49].
All samples were assayed in technical triplicates. Briefly, the
PCR reaction mix was prepared by mixing 0.125 μl 20× gene
expression assay and 5 μl 2× Gene Expression Master Mix
(Applied Biosystems Inc.) per reaction. Then, 50 ng cDNA
(5 μl of 10 ng/μl stock solution) was pipetted into each well,
followed by 5 μl of the prepared master mix, yielding a 10 μl
reaction. The prepared plate was incubated at 50 °C for 2 min
and  at  95  °C  for  10  min,  followed  by  40  PCR  with  the
following specifications: 1) 95 °C – 15 s; 2) 60 °C – 1 min.
Relative amounts of gene transcript were determined using
SDS 2.2.2 software (Applied Biosystems Inc.) and the 2-ΔΔCt
method with β-actin (Actb) as the endogenous control [52,
53].
Statistical  analyses:  Serum  glucose  concentrations  and
transcript  expression  data  were  analyzed  by  one-way
ANOVA  (ANOVA)  with  Student–Newman–Keuls  (SNK)
post-hoc  testing  with  α<0.05.  For  the  gene  expression
analysis, a Benjamini-Hochberg multiple testing correction
was applied to the one-way ANOVA across the 36 genes
examined to control for Type I false positive errors [54]. For
any data that failed normality testing, a Kruskal–Wallis one-
way ANOVA on ranks was performed using SigmaStat 3.5
(Systat Software, San Jose, CA). Potential overrepresentation
of genes commonly regulated with aging and diabetes was
tested  using  a  binomial  distribution,  assuming  the
independence of each gene and equal distribution of increases
and decreases in gene expression by random chance. Principal
component analysis was used to visualize the relationship
between groups. Individual animal data for Young, Adult, and
Aged rats from all 36 genes quantitated were normalized to
mean Young values and imported into GeneSpring GX 11.0.
Likewise, previously reported expression data for 3-month
diabetic and nondiabetic control rats [45,46,49] were scaled
to mean control values for comparison with age-group data.
The first two principal components were mean centered and
scaled, and plotted with individual animal data compressed to
represent each group as a single point. Potential common
transcriptional regulators were assessed by Ingenuity Pathway
Analysis (Ingenuity Systems, Redwood City, CA).
RESULTS
Serum  glucose:  Serum  glucose  levels  at  sacrifice  were
assessed  to  confirm  normoglycemia.  The  average  serum
glucose level in Young animals was 5.24 nM±0.7 (94 mg/dl),
6.72 nM±0.8 (121 mg/dl) in Adult animals, and 5.60 nM±0.5
(101  mg/dl)  in  Old  animals  (Figure  1).  All  groups  were
normoglycemic  and  no  statistically  significant  differences
were found between the groups. No individual animals were
hyperglycemic (>250 mg/dl).
Retinal mRNA expression: To evaluate potential similarities
between retinal transcript expression changes with aging and
diabetes,  36  gene  targets  from  our  previously  described
analyses of DR [45-48] were quantitated in Young, Adult, and
Aged  rats  by  quantitative  PCR.  Our  previous  analyses  of
retinal gene expression with diabetes have shown that these
transcripts are differentially expressed in a highly consistent
manner across multiple experiments [46]. Of the 36 genes
examined,  14  were  differentially  expressed  (one-way
ANOVA, Benjamini-Hochberg multiple testing correction,
p<0.05). Eleven genes were increased similarly to what we
have  previously  demonstrated  with  diabetes.  Three  genes
were regulated in a direction opposite to that seen in diabetes.
More  genes  were  regulated  in  the  same  direction  and
magnitude with aging and diabetes than would be expected by
chance (p=0.028), assuming a random distribution. To test for
the potential coregulation of these genes, Ingenuity Pathway
Analysis was performed and no transcription factors or other
transcriptional regulators were identified as common to more
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more  complex  regulatory  networks  that  are  not  currently
understood may be commonly engaged by aging and diabetes,
which would affect the assumption of a random distribution.
Although these genes have multiple functions, they can be
separated into three distinct groups according to our previous
analyses  [45]:  inflammation-related  genes,  microvascular-
related genes, and neuronal function–related genes.
Inflammatory  transcripts:  For  the  genes  associated  with
inflammatory  processes,  most  of  the  changes  were
Figure 1. Serum glucose levels measured at sacrifice. Non-fasting
serum glucose levels were measured at sacrifice. All glucose levels
were  normoglycemic  and  no  differences  between  groups  were
observed. One-way ANOVA (ANOVA) with Student–Newman–
Keuls  (SNK)  post  hoc  test,  n=5–6/group.  Error  bars  represent
standard error of the mean.
upregulations  with  age.  Retinal  transcript  expression  of
complement  component  1  s  subcomponent  (C1s),  glial
fibrillary acidic protein (Gfap), lipopolysaccharide-induced
TNF factor (Litaf), chitinase 3-like 1 (Chi3L1), janus kinase
3 (Jak3), and signal transducer and activator of transcription
3  (Stat3)  was  significantly  higher  in  Adult  animals  when
compared to Young animals. Additionally, these transcripts
showed significantly higher expression in Aged versus both
Young and Adult animals (Figure 2). Complement 1-inhibitor
I (Serping1) and tumor necrosis factor receptor subfamily
member 12a (Tnfrsf12a) demonstrated a similar pattern of
expression with significantly higher expression levels in Aged
versus both Young and Adult animals. Guanylate nucleotide
binding  protein  2  (Gbp2)  expression  was  significantly
elevated in Aged and Adult versus Young animals. Pigment
epithelium-derived growth factor (Pedf) showed significantly
lower  expression  levels  in  both  Adult  and  Aged  animals
compared to the Young group. Additional genes examined (X-
linked inhibitor of apoptosis [Birc4], calcium regulated heat
stable protein 1 [Carhsp1], chemokine CC motif receptor 5
[Ccr5], elongation of very long chain fatty acids [Elovl1], heat
shock 27 kDa protein 1 [Hspb1], lectin galactoside-binding
soluble  3  [Lgals3],  lectin  galactoside-binding  soluble  3
binding  protein  [Lgals3bp],  methylcrotonoyl-CoA
carboxylase 1 [Mccc1], nuclear receptor subfamily 3 group C
member  1  [Nr3c1],  signal  transducer  and  activator  of
transcription  1  [Stat1],  and  tissue  inhibitor  of
metalloproteinase  1  [Timp1])  did  not  differ  in  expression
between groups (Table 2). With the exception of Pedf, all of
the age-related gene expression changes were induced in a
similar fashion to what was seen in diabetes (Table 3).
Microvascular  transcripts:  Of  the  microvascular-related
transcripts measured, endothelin 2 (Edn2) and intracellular
adhesion molecule 1 (Icam1) were both found to significantly
increase in expression in the retina with age (Figure 3). In
particular,  Edn2  showed  significantly  higher  expression
levels in the Aged versus Young and Adult rats, as well as in
Adult versus Young rats (Kruskal–Wallis one-way ANOVA
on  ranks,  p<0.05).  Similarly,  Icam1  showed  significantly
higher expression in Aged versus Young and Adult versus
Young animal comparisons (SNK, p<0.001). No differences
in expression of endothelin receptor B (Ednrb), natriuretic
peptide precursor A (Nppa), or vascular endothelial growth
factor A (Vegfa) were observed between age groups (Table
2). Similar to the age-related gene expression changes, both
Edn2 and Icam1 showed significantly higher expression in
rats with diabetes compared to nondiabetic controls (Table 3).
Neuronal function transcripts: Two genes associated with
neuronal  function  were  also  found  to  be  significantly
regulated with age in the rat retina (Figure 4). Polycomb group
ring  finger  1  (Pcgf1)  demonstrated  significantly  higher
transcript levels when comparing Aged rats to Young ones
(SNK, p<0.005). Glutamate receptor ionotropic NMDA 2A
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expression  in  Aged  than  Young  rats  (Student–Newman–
Keuls [SNK], p=0.007) or Adult animals (SNK, p<0.001).
However, Grin2a levels significantly decreased in Young as
compared to Adult animals (SNK, p=0.002). Bardet-Biedl
syndrome 2 (Bbs2), doublecortin-like kinase 1 (Dcamkl1),
enolase 2 (Eno2), GABA transporter 3 (Gat3), isk-related
voltage-gated K+ channel 2 (Kcne2), and neurofilament heavy
polypeptide (Nefh) showed no significant differences between
age groups (Table 2). In contrast to these results, Pcgf1 and
Grin2a  showed  significantly  decreased  expression  with
diabetes as compared to nondiabetic controls (Table 3).
To visualize the relationship of gene expression profiles
between  age  groups  and  our  previously  published
characterizations  of  the  rat  retina  after  three  months  of
diabetes, a principal component analysis was performed. The
principal component analysis was used to combine all of the
data into one visualization showing the relationship of the
expression  patterns  from  the  different  groups.  For  the
purposes of this study, each gene was plotted on its own axis
to form a multidimensional space from which the principal
components were identified in order of decreasing variance.
This permits visualization of the most significant relationships
between groups in a standard two-dimensional plot, when the
first two components are plotted. Retinal gene expression data
was scaled to the mean of the Young group for each gene. Data
from diabetic and nondiabetic controls were scaled to the
mean  of  the  controls  on  a  gene-by-gene  basis.  The  first
component accounted for 74% of variance between groups,
progressively separating the Young and Nondiabetic Control
from the Adult, Aged, and Diabetic rats along the x-axis
(Figure 5); this was interpreted as gene expression changes
with  diabetes.  The  second  component  (26%  of  variance)
separated  the  Young,  Nondiabetic  Control,  and  Diabetic
groups from the Adult and Aged groups along the y-axis. This
component was interpreted as representing the age-specific
changes  in  gene  expression.  In  total,  this  visualization
demonstrates that while there are some commonalities in gene
expression  patterns  with  diabetes  and  aging,  they  are  not
superimposable molecular phenotypes.
Figure 2. Inflammation transcripts are
regulated  with  aging.  Ten  of  the  23
inflammation-related transcripts that we
have  previously  observed  to  be
upregulated in the retina of a rat model
of  Type  I  diabetes  were  significantly
altered with age. With the exception of
pigment  epithelium-derived  growth
factor (Pedf), all of the transcripts were
upregulated in Old animals. One-way
ANOVA  (ANOVA)  with  Benjamini-
Hochberg  multiple  testing  correction,
##p<0.01, ###p<0.001; SNK post-hoc
test,  *p<0.05,  **p<0.01,  ***p<0.001,
n=5/group.  Error  bars  represent
standard error of the mean.
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Aging is a primary risk factor for vision loss. With increasing
age,  functional  and  structural  characteristics  of  the  retina
decline, as is demonstrated by aberrant psychophysical and
electrophysiological  measures  of  stimulus  response,
impairment  of  vascular  integrity,  and  activation  of
inflammatory  signaling.  Numerous  aspects  of  retinal
dysfunction  with  normal  aging  share  commonalities  with
pathological  changes  and  functional  deficits  induced  with
diabetes [10,22,50,55,56]. Commonalities between aging and
diabetes  have  been  reported  in  both  the  CNS  and  the
periphery, and have led to the hypothesis that diabetes may
induce an “accelerated aging” phenotype. The goal of this
study  was  to  characterize  age-related  retinal  expression
profiles of neurovascular and inflammatory transcripts, using
targets previously determined to be regulated with diabetes.
Many of the transcripts investigated exhibited progressively
increased expression with increasing age, in agreement with
functional  data  indicating  generalized  age-related
neurovascular inflammation in the retina and consistent with
the concept of para-inflammation [57]. The functions of these
genes  and  their  protein  products,  as  well  as  the  potential
implications of their dysregulation with aging, are discussed
below.
Microvasculature:  Previous  investigations  of
microvascular  dysfunction  with  retinal  aging  have
demonstrated declining RPE cell integrity [58], microvascular
lesions [56,59], increased vessel leakage, and vascular cell
apoptosis  [22].  In  the  aged  retina,  decreased  occludin
expression is associated with increased vascular permeability
[20] and RPE dysfunction, although the specific biochemical
mechanisms of declining vascular integrity remain to be fully
determined.  We  have  previously  demonstrated  that
Edn2,Ednrb,Icam1,Nppa,  and  Vegfa  showed  significantly
altered expression patterns in the diabetic rat retina when
compared to nondiabetic controls [45]. Icam1 and Edn2 are
increased with diabetes and show similar magnitude increases
in expression with age. Icam1 is elevated in patients diagnosed
with  proliferative  DR,  and  contributes  to  blood-retinal
breakdown and DR development [60-62]. Our findings agree
with a previous report of increased retinal Icam1 expression
with  advanced  age  [62].  Icam1  has  been  implicated  in
leukocyte cell adhesion to the retinal vascular endothelium in
the diabetic retina, promoting leukostasis and therefore retinal
TABLE 2. TRANSCRIPTS NOT REGULATED WITH AGE.
Gene Young Adult Old Function
Birc4 1.0±0.05 1.0±0.03 0.9±0.03 Inflammation
Carhsp1 0.9±0.07 1.0± 0.13 1.0±0.17  
Ccr5 1.0±0.03 1.0± 0.04 1.0±0.03  
Elovl1 1.0±0.06 1.0± 0.04 0.9±0.04  
Hspb1 0.9±0.13 1.0± 0.06 1.1±0.08  
Lama5 1.1±0.06 1.0± 0.06 1.1±0.07  
Lgals3 1.1±0.08 1.0± 0.05 1.1±0.08  
Lgals3bp 1.0±0.05 1.0±0.03 0.9±0.03  
Mccc1 1.0±0.05 1.0± 0.04 1.0±0.04  
Nr3c1 0.9±0.06 1.0± 0.02 1.1±0.05  
Stat1 1.0±0.04 1.0± 0.06 1.2±0.07  
Timp1 1.0±0.03 1.0± 0.06 1.1±0.09  
Ednrb 1.0±0.05 1.0± 0.06 1.0±0.08 Microvasculature
Nppa 0.9±0.02 1.0±0.16 1.1±0.06  
Vegfa 1.0±0.08 1.0±0.03 1.1±0.06  
Bbs2 1.0±0.05 1.0±0.03 1.0±0.05 Neuronal function
Dcamkl1 1.0±0.05 1.0± 0.11 1.0±0.06  
Eno2 1.0±0.05 1.0± 0.02 1.0±0.04  
Gat3 1.0±0.05 1.0± 0.05 1.0±0.05  
Igf2 0.8±0.05 1.0± 0.05 1.0±0.04  
Kcne2 1.1±0.08 1.0± 0.09 0.9±0.07  
Nefh 1.0±0.04 1.0±0.03 1.1±0.05  
         Data are presented as mean±SEM (n=5/group) for genes which were not significantly regulated with age (Benjamini Hochberg
         multiple testing corrected one-way ANOVA with Student–Newman–Keuls (SNK) post-hoc testing or Kruskal–Wallis One-Way
         ANOVA on Ranks if the data failed normality testing).
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expression  with  aging  could  work  additively  in  aging
diabetics to increase the risk of microvascular dysfunction.
Edn2 is a strong vasoconstrictor and regulator of ocular blood
flow [64]. As blood flow abnormalities are observed with both
diabetes and aging, the common upregulation of Edn2 may
represent a common causative factor. Edn2 expression has
been  localized  to  photoreceptors  and  signals  through  the
Ednrb receptor on Müller cells [65]. This signaling may serve
as an integration point between microvascular dysfunction,
microglial activation, and inflammation, which are observed
in both diabetes and aging.
One interesting finding was that there was no change in
Vegf with age in the retina. Previously, we have consistently
identified a modest but significant decrease in Vegf mRNA in
a streptozotocin (STZ)-induced rat model of diabetes [45,
46]. While induction of retinal Vegf protein in late-stage DR
patients has been described, data on the exact time course of
TABLE 3. GENES PREVIOUSLY CHARACTERIZED IN RAT RETINA WITH DIABETES.
Gene Diabetic/Control p-value
Bbs2 ↓ 40% ***
Birc4 ↓ 30% ***
C1-INH ↑ 160% **
C1S ↑ 180% **
Carhsp1 ↑ 160% ***
Ccr5 ↑ 60% **
Chi3L1 ↑ 170% **
Dcamkl1 ↓ 20% **
Edn2 ↑ 270% *
Ednrb ↑ 60% **
Elovl1 ↓ 50% ***
Eno2 ↓ 20% *
Gat3 ↓ 40% ***
Gbp2 ↑ 140% *
Gfap ↑ 400% **
Grin2a ↓ 40% ***
Hspb1 ↑ 1320% **
Icam1 ↑ 70% **
Igf2 ↓ 50% ***
Jak3 ↑ 90% **
Kcne2 ↓ 50% ***
Lama5 ↑ 80% ***
Lgals3 ↑ 700% ***
Lgals3bp ↑ 70% **
Litaf ↑ 70% *
Mccc1 ↓ 20% **
Nefh ↓ 20% *
Nr3c1 ↓ 20% *
Nppa ↓ 50% ***
Pcgf1 ↓ 30% *
Pedf ↑ 90% *
Stat1 ↑ 30% *
Stat3 ↑ 40% **
Timp1 ↑ 300% **
Tnfrsf12a ↑ 120% ***
Vegfa ↓ 40% ***
        Data represent gene expression in the diabetic rat retina as a percent of control values. Two-tailed t-test *p<0.05, ** p<0.01,
        *** p<0.001. From [44,45,47].
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being unchanged at 3 months [66], increased at 6 months
[67], and decreased at 6 months [68] of STZ-induced diabetes
in the rat.
Neuronal function: Neuronal dysfunction and vision loss
with  aging  are  well  characterized  at  the  psychophysical,
electrophysiological,  and  biochemical  levels,  and  suggest
broad  impairment  of  the  neural  retina  that  affects
photoreceptors, interneurons, and ganglion cells [9,10,13].
Our previous studies have shown marked alterations in the
expression of Bbs2, Dcamkl1, Eno2, Gat3, Grin2a, Kcne2,
Nefh, and Pcgf1 in the diabetic retina (Table 3). Of these
genes, two (Pcgf1 and Grin2a) were found to be regulated
with  age.  Pcgf1  increased  significantly  with  age  while
Grin2a  showed  decreased  expression  in  Adults  when
compared  to  Young  animals,  yet  Aged  animals  showed
significantly increased expression when compared to both
Young and Adult animals. These results are interesting, as
Figure 3. Microvascular transcripts are regulated with aging. Two of
the five microvascular-related transcripts that we have previously
observed to be upregulated in the retina of a rat model of Type I
diabetes  were  significantly  altered  with  age.  One-way  ANOVA
(ANOVA) with Benjamini-Hochberg multiple testing correction,
###p<0.001; SNK post-hoc test, *p<0.05, **p<0.01, ***p<0.001,
n=5/group. Error bars represent standard error of the mean.
both of these genes show a general upregulation with age
while  with  diabetes,  they  were  found  to  show  significant
downregulation.
Pcgf1, also known as Nspc1 (nervous system polycomb
1), is a novel transcriptional repressor that is highly expressed
in  the  developing  nervous  system.  This  gene  has  been
demonstrated to be responsive to protein kinase C (PKC)
signaling  and  has  also  been  shown  to  be  associated  with
epigenetic mechanisms of gene transcription regulation [69,
70]. Upregulation of this gene in aged animals could alter
transcriptional control of genes regulated by Pcgf1, either
directly  (functioning  as  a  transcriptional  repressor)  or
indirectly (functioning as an epigenetic modifier). Further
gene-specific studies of Pcgf1 are needed to determine the
specific target genes regulated by Pcgf1.
Grin2a  (glutamate  receptor,  ionotropic,  N-methyl  D-
aspartate 2A) encodes the glutamatergic NMDAR2a receptor
responsible for excitatory neurotransmission. Although the
function  of  this  receptor  is  unknown  in  the  retina,  the
heteromeric subunit composition of the NMDA receptor is
associated  with  variations  in  excitotoxicity  [71].  Grin2a
Figure 4. Neuronal function transcripts are regulated with aging. Two
of  the  10  neuronal  function–related  transcripts  that  we  have
previously observed to be upregulated in the retina of a rat model of
Type I diabetes were significantly altered with age. Polycomb group
ring finger 1 (Pcgf) increased with age while glutamate receptor
ionotropic NMDA 2A (Grin2a) decreased in Adult animals and
increased in the Aged animals. One-way ANOVA (ANOVA) with
Benjamini-Hochberg  multiple  testing  correction,  #p<0.05;  SNK
post-hoc test, *p<0.05, **p<0.01, ***p<0.001, n=5/group. Error
bars represent standard error of the mean.
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decreasing in adulthood as compared to Young animals, while
seeming to overcompensate and show the highest expression
in Aged animals. This could be a maladaptive compensatory
response to other changes in neuronal gene expression and
diminished neurotransmission that occur with advanced age,
given the sharp increase in expression found specifically in
the  Aged  animals.  The  functional  outcome  of  increased
Grin2a could facilitate neurotransmission, but also result in
excitotoxicity and the induction of downstream inflammatory
processes. The hypothesis seems to be plausible given the
higher  Grin2a  expression  in  both  the  Young  and  Aged
animals.
Inflammation:  Age-related  increases  in  inflammatory
processes are reported throughout the CNS. In the retina,
vascular dysfunction likely contributes to proinflammatory
signaling  in  a  feed-forward  cycle  due  to  loss  of  barrier
integrity, toxic drusen deposition, and monocyte infiltration
[17,72].  Increased  microglial  activation,  indicated  by  the
presentation of MHC class II- and ED1-immunoreactive cells,
has been reported in the retinal parenchyma in aged rats [20].
In  aged  mice  (20  months),  markers  of  para-inflammation
observed in this study (C1s, Gpb2, Icam1, and Spering1) have
been reported [62]. Furthermore, elevated circulating levels
of  the  proinflammatory  glycoprotein  Chi3L1  have  been
demonstrated in aged humans (>80 years) compared with
younger  adults  (18–30  years)  [19].  Oxidative  stress,  the
Figure 5. Principal component analysis demonstrates relationship
between  patterns  of  aging-  and  diabetes-induced  retinal  gene
expression. To visualize the relationship of gene expression profiles
across age groups, a principal component analysis was performed
using genes determined to be significantly regulated with aging. A
clear progression in expression profiles was evident with increasing
age, and created a continuum ranging from the Young to Adult to
Aged  group.  Previously  reported  expression  data  for  3-month
diabetic and nondiabetic control rats, aged 4 months, were included
in this analysis. Diabetic rats were separated from controls in a
similar manner to the Aged group, demonstrating commonalities in
expression changes and lending support to the hypothesis of diabetes
as a form of accelerated aging.
accumulation of photoreactive pigments, necrotic/apoptotic
cells, and leukocyte infiltration have been implicated in the
activation  of  inflammatory  pathways  involving  these  and
other proinflammatory molecules.
A hallmark of DR is a marked increase in the expression
of genes involved in the regulation of inflammatory processes.
We have previously demonstrated that Birc4, Carhsp1, C1-
Inh  (Serping1),  C1s,  Ccr5,  Cd44,  Chi3L1,  Elovl1,  Gbp2,
Gfap, Hspb1, Jak3, Lama5, Lgals3, Lgals3bp, Litaf, Mccc1,
Nr3c1, Pedf, Stat1, Stat3, Timp1, and Tnfrsf12a significantly
change in expression in the diabetic retina. Of these genes, 10
were  found  to  be  regulated  with  aging,  specifically  C1s,
Chi3L1, Gbp2, Gfap, Jak3, Litaf, Pedf, Serping1, Stat3, and
Tnfrsf12a. All of these genes increased in expression with DR,
and several have been previously reported to change with
aging  in  the  CNS.  Interestingly,  similar  increases  in
expression were seen with age in all genes except Pedf, which
was actually found to significantly decrease in expression.
C1s  (complement  component  1,  s  subcomponent)
encodes a serine protease that is a subunit of the complement
subcomponent C1 complex, which is involved in activation
of the complement system. Although the exact role of C1s
upregulation in DR and aging is unknown, it has been shown
to  be  expressed  in  retinal  ganglion  cells.  Interestingly,
elevated C1s expression was observed with retinal ganglion
cell death in response to serum depravation, suggesting a role
for the complement pathway in regulating neuronal cell death
in the retina [73]. Therefore, elevated expression of C1s could
be indicative of complement pathway activation and increased
inflammation  in  response  to  retinal  ganglion  cell  death.
Furthermore, Chi3L1 (chitinase 3–like 1) is an inflammatory
glycoprotein  secreted  by  activated  macrophages  and  is
suggested to be involved in innate immune system activation,
macrophage differentiation, extracellular matrix remodeling,
and vascular cell migration [74]. Our tissue-specific findings
agree with clinical reports of increased plasma Chi3L1 levels
in Type 1 and Type 2 diabetic subjects [75,76]. Elevated
Chi3L1 expression in the retina implies a general increase in
retinal inflammation with both diabetes and aging. Although
the  exact  role  of  Gbp2  (guanylate  binding  protein  2,
interferon-inducible),  an  interferon-inducible  GTPase,  is
unknown in the pathology of DR, our previous studies have
shown a significant increase in expression in diabetic animals
when compared to nondiabetic controls [46].
Gfap (glial fibrillary acidic protein) is an intermediate
filament protein highly expressed in astrocytes that has been
shown  to  be  differentially  expressed  with  DR.  Increased
Gfap  expression  in  Müller  cells  with  diabetes  has  been
described  previously  [44,68],  and  we  have  observed  the
insulin  therapy–resistant  induction  of  Gfap  mRNA  with
diabetes [49]. The step-wise induction of Gfap with increasing
age is prototypical of increased para-inflammation with aging.
Jak3 (janus kinase 3) is a proinflammatory component of the
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transducer and activator of transcription 3). This pathway
regulates  cytokine  signaling  and  inflammatory  responses
[77]. Upregulation of Jak3 and Stat3 signaling with aging can
induce a broad range of acute phase and other inflammatory
mediators. The transcription factor Litaf (lipopolysaccharide-
induced TNF factor) regulates the production of TNF-α, a
potent and well characterized proinflammatory cytokine in the
retina  [78].  Our  studies  have  demonstrated  significant
increase in Litaf expression with both DR and age, suggesting
increased levels of inflammation. Tnfrsf12a (tumor necrosis
factor receptor superfamily, member 12 A; aka Tweakr, Fn14)
is the receptor for TNF-related weak inducer of apoptosis
(Tweak)  which  is  a  proinflammatory  cytokine.  Previous
studies  have  demonstrated  that  Tnfrsf12a  activation  via
Tweak has proinflammatory effects in RPE cells [79] and
produces more highly vascularized tumors in athymic mice
[80]  suggesting  both  proinflammatory  and  proangiogenic
effects with increased expression.
Contrary to the genes described above, Pedf (pigment
epithelium derived factor) has anti-inflammatory properties
and has been found to be enriched in the serum of patients
with Type 1 diabetes with DR [81]. In one study, Pedf was
able to inhibit the migration of cultured endothelial cells in a
dose-dependent  manner,  suggesting  its  ability  to  decrease
neovascularization [82]. Additionally, a recent report showed
how  Pedf  was  able  to  decrease  advanced  glycation  end-
product (AGE)-induced endothelial cell permeability, further
suggesting  that  Pedf  plays  a  role  in  counteracting
angiogenesis  associated  with  DR  [83],  and  AGE-induced
inflammation with aging and diabetes [55]. Decreased Pedf
expression in the adult and aged retina would diminish a
critical  protective  mechanism  against  AGE/AGE  receptor
(RAGE)-induced  inflammation,  leaving  the  retina  more
susceptible  to  a  variety  of  physiologic  insults.  Serping  1
(serpin peptidase inhibitor, clade G [C1 inhibitor], member 1),
also known as C1-Inh, is an inhibitor of the complement
system  activation.  Patients  with  DR  show  increased
expression of Serping1, which serves to protect the integrity
of the vascular endothelium in the retina [84]. Unlike the
diminished expression of Pedf, this protective mechanism is
induced with age.
Taken together, the induction of proinflammatory genes
(C1s, Chi3L1, Gbp2, Gfap, Jak3, Litaf, Stat3, and Tnfrsf12a)
and reduction of the anti-inflammatory Pedf indicate a para-
inflammatory state with increasing age in the retina [50]. This
generalized  proinflammatory  state  could  help  explain  the
increased vulnerability for retinal diseases such as DR and
macular  degeneration  with  increasing  age.  The  potential
mechanisms leading to the para-inflammatory state observed
with increasing age include retinal stress through reactive
oxygen species and AGEs. The commonalities in retinal gene
expression changes occurring in young hyperglycemic and
aged normoglycemic rats indicate that different stressors can
lead to some, but not all, of the same inflammatory processes.
Clearly,  additional  research  is  needed  to  build  upon  the
existing knowledge related to retinal para-inflammation with
aging [62].
These results demonstrate altered retinal gene expression
across  the  adult  rat  lifespan  in  a  set  of  genes  previously
demonstrated to be altered in expression with diabetes. While
this analysis focused on a predetermined set of genes, these
results  provide  the  rationale  for  future  genome-wide
comparisons of retinal transcriptomic changes with aging and
diabetes, as well as comparative analysis of retinal proteomic
alterations. For both molecular and biochemical analyses, use
of isolated retinal cell types, such as those previously reported
(e.g., Müller [68], photoreceptors [23]), will provide a clearer
picture of the altered pathways and processes with aging and
diabetes in retinal cell types. While technically challenging,
cell-specific analyses of in vivo models is needed to more
clearly tie altered RNA/protein expression to dysfunction in
specific cell types and to define gene expression regulatory
networks that may be commonly engaged with aging and
diabetes. Prospective studies across the lifespan, including
induction of diabetes at different ages, will provide more
specific insight into whether the effects of aging and diabetes
are additive.
The  specific  inflammatory,  neuronal  function,  and
microvascular  genes  altered  with  aging  provide  potential
molecular mechanisms for the well documented functional
impairments and para-inflammatory state of the retina with
advanced  age.  Additionally,  these  results  support  the
hypothesis  that  diabetes  and  aging  share  some  common
molecular  alterations.  However,  these  results  also
demonstrate  that  the  patterns  of  gene  expression  with
advanced  age  and  diabetes  are  not  identical.  Age-related
changes  in  retinal  gene  expression  indicative  of  para-
inflammation may work synergistically with the same para-
inflammatory processes induced by diabetes to accelerate DR
pathogenesis. Given the growing incidence of diabetes and
increasing  longevity  [85],  further  investigation  of  the
contribution of age-related retinal gene expression alterations
to retinal diseases common in the aged population is needed.
The microvascular and inflammatory processes observed in
this  study  may  also  serve  as  targets  for  development  of
therapies that prevent or treat age-related retinal dysfunction.
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